Johnson & Johnson (NYSE:JNJ) Shares Acquired by UP Strategic Wealth Investment Advisors LLC

UP Strategic Wealth Investment Advisors LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 18.0% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,532 shares of the company’s stock after purchasing an additional 234 shares during the quarter. UP Strategic Wealth Investment Advisors LLC’s holdings in Johnson & Johnson were worth $224,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in JNJ. Innealta Capital LLC purchased a new position in Johnson & Johnson during the 2nd quarter worth approximately $27,000. Christopher J. Hasenberg Inc acquired a new position in shares of Johnson & Johnson in the 1st quarter valued at $31,000. MFA Wealth Advisors LLC purchased a new stake in Johnson & Johnson in the 2nd quarter valued at $43,000. Vermillion & White Wealth Management Group LLC acquired a new stake in Johnson & Johnson during the 4th quarter worth $44,000. Finally, Fairfield Financial Advisors LTD acquired a new position in Johnson & Johnson in the second quarter valued at $46,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $166.17 on Thursday. The business has a 50 day moving average price of $160.71 and a 200 day moving average price of $154.09. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. The company has a market capitalization of $399.92 billion, a P/E ratio of 10.36, a PEG ratio of 2.71 and a beta of 0.53. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, topping the consensus estimate of $2.71 by $0.11. The business had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The business’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.80 EPS. Sell-side analysts expect that Johnson & Johnson will post 10.02 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 2.98%. The ex-dividend date of this dividend was Tuesday, August 27th. Johnson & Johnson’s payout ratio is currently 30.92%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on JNJ shares. The Goldman Sachs Group decreased their target price on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research note on Friday, July 19th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. Morgan Stanley upped their price target on Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 18th. Daiwa Capital Markets lowered shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and lowered their price objective for the company from $160.00 to $150.00 in a research report on Tuesday, July 23rd. Finally, TD Securities cut their price objective on shares of Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $173.21.

Insider Buying and Selling at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now directly owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.16% of the stock is owned by insiders.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.